Thoracic Clinical Trials

With an emphasis on transdisciplinary translational research, the OSUCCC-James facilitates investigator-initiated early phase clinical trials and participates in many cooperative groups.

Protocol No.PITitle
OSU-12117Erin BertinoA Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
OSU-12226Erin BertinoA Phase I Study of BMS-986015, an Anti-KIR Monoclonal Antibody, Administered with Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Subjects with Select Advanced Solid Tumors
OSU-13087Erin BertinoAn Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-Line Therapy to Patients with Non-Small Cell Lung Cancer
OSU-12012Kristy BrowningDeveloping an ePersonal Health Record (PHR) for delivery of tobacco dependence treatment to oncology patients who smoke
OSU-13095Bo ChaoA Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients with PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
OSU-13100Bo ChaoA phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum doublet) and crizotinib
OSU-13118Bo ChaoDouble blind, randomised, multicentre, phase II study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed / cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma
OSU-13035Bo ChaoA Phase 2 Study of Neratinib and Neratinib Plus Temsirolimus in Patients with Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations
OSU-12119Bo ChaoA Phase I/II Study of the ALK Inhibitor CH5424802 in Patients with ALK-Rearranged Non-Small Cell Lung Cancer
OSU-13044Michael EzziePulmonary Rehabilitation in locally advanced Non-Small Cell Lung Cancer
CALGB-30610John GreculaPhase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide
OSU-08111John GreculaMR-Predictive-Assay in Pre-Operative Lung Cancer Therapy: Response/Resectability
CALGB-150712John GreculaEmbedded Companion Study to CALGB 30610
CALGB-70702John GreculaEmbedded Companion to CALGB 30610
OSU-09027Edward KimUse of PET-CT in Neoadjuvant Chemoradiation Therapy for Stage IIIA NSCLC
CALGB-150704Kavitha KosuriEmbedded Companion Study to CALGB-30605
CALGB-70701Kavitha KosuriEmbedded Companion Study to CALGB-30607
CALGB-60702Kavitha KosuriEmbedded Companion Study to CALGB-30607
CALGB-150707Kavitha KosuriEmbedded Substudy "A Phase II Study of Dasatinib (NSC # 732517) in Patient w/ Previously Treated Malignant Mesothelioma"
OSU-07115Susan Moffatt-BruceImmunobiology of Photodynamic Therapy in Lung Cancer Patients
OSU-08113Ryan NiederkohrRetrospective Evaluation of the Prognostic Value of Total Tumor Volume Versus SUV in Patients with Lung Cancer Undergoing FDG PET/CT
CALGB-70809Greg OttersonEmbedded Companion to CALGB-30506: Quality of Life in Patients on CALGB-30506
CALGB-150701Greg OttersonEmbedded Companion Study to CALGB-30504
CALGB-60705Greg OttersonEmbedded Companion Study to CALGB 30704
CALGB-580702Greg OttersonEmbedded Campanion Study to CALGB 30704
CALGB-151108Greg OttersonCORRELATIVE IMAGING ANALYSIS OF CALGB 30406: ERLOTINIB THERAPY IN LUNG CANCER AS A MODEL FOR THE DEVELOPMENT OF BIOLOGICALLY MEANINGFUL RESPONSE METRICS
OSU-12169Greg OttersonPHASE 1 SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF PF-02341066, A C-MET/HGFR SELECTIVE TYROSINE KINASE INHIBITOR, ADMINISTERED ORALLY TO PATIENTS WITH ADVANCED CANCER
OSU-12184Greg OttersonLung Cancer Mutation Consortium Protocol
OSU-12053Greg OttersonA Randomized Phase II Trial of Erlotinib Alone or In Combination with Bevacizumab in Patients With Non-Small Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations
ECOG-E5508Greg OttersonRandomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
CALGB-150908Greg OttersonEmbedded Protocol to CALGB-30801
CALGB-60904Greg OttersonEmbedded Companion Studu to CALGB-30801
CALGB-150912Greg OttersonEmbedded Companion Study to CALGB-30901
CALGB-580903Greg OttersonEmbedded Companion Study to CALGB-30901
OSU-12072Patrick RossPhotodynamic Therapy (PDT) Oncology Registry
OSU-12210Patrick RossRobotic-Assisted Thoracic Surgery (RATS) Patient Registry: PROTOCOL
CALGB-140503Patrick RossA Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small < 2cm Peripheral Non-Small Cell Lung Cancer
OSU-07082Miguel VillalonaAnalysis of FANCD2 Protein Monoubiquitin Status and Nuclear Foci Formation in the Primary Solid Tumors
OSU-09100Miguel VillalonaABT-888 as monotherapy and in combination with Mitomycin C in patients with solid tumors with deficiency in homologous recombination repair.
OSU-12167Miguel VillalonaA Phase II study of the BRAF inhibitor dabrafenib as a single agent and in combination with the MEK inhibitor trametinib in subjects with BRAF V600E mutation positive metastatic (stage IV) non-small cell lung cancer
RTOG-0937Meng WelliverRANDOMIZED PHASE II STUDY COMPARING PROPHYLACTIC CRANIAL IRRADIATION ALONE TO PROPHYLACTIC CRANIAL IRRADIATION AND CONSOLIDATIVE EXTRA-CRANIAL IRRADIATION FOR EXTENSIVE DISEASE SMALL CELL LUNG CANCER (ED-SCLC)

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu